Evaluation of Long-Term Safety and Tolerability of ETC-1002 in High-Risk Patients With Hyperlipidemia and High CV Risk (CLEAR Harmony)

Phase 3

Completed

• Conditions: Hypercholesterolemia; Atherosclerotic Cardiovascular Diseases
• Interventions: Drug: Placebo; Drug: ETC-1002

• Registration Number: NCT02666664
• Lead Sponsor: Esperion Therapeutics, Inc.

Brief Summary

The purpose of this study is to see if ETC-1002 (bempedoic acid) is safe and well-tolerated versus placebo in patients with high cardiovascular risk and elevated LDL cholesterol that is not adequately controlled by their current therapy.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2016-01-20
• Study Start: 2016-01-21
• Study First Submitted QC: 2016-01-25
• Study First Posted: 2016-01-28
• Primary Completion: 2018-02-21
• Study Completion: 2018-03-28
• Disposition First Submitted: 2018-07-23
• Disposition First Submitted QC: 2018-07-23
• Disposition First Posted: 2018-07-26
• Results First Submitted: 2020-03-20
• Status Verified: 2020-04
• Results First Submitted QC: 2020-04-08
• Results First Posted: 2020-04-20
• Last Update Submitted: 2020-04-24
• Last Update Posted: 2020-05-11

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 2230

Inclusion Criteria

• Fasting LDL-C ≥ 70 mg/dL
• High cardiovascular risk (diagnosis of HeFH or ASCVD)
• Be on maximally tolerated lipid-modifying therapy

Read More

Exclusion Criteria

• Total fasting triglyceride ≥500 mg/dL
• Renal dysfunction or nephrotic syndrome or history of nephritis
• Body Mass Index (BMI) ≥50kg/m2
• Significant cardiovascular disease or cardiovascular event in the past 3 months

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Placebo	Placebo	Placebo control
ETC-1002	ETC-1002	ETC-1002 180 mg/day

Primary Outcome Measures

Name	Time	Method
Percentage of Participants With Adjudicated Major Adverse Cardiovascular Event	Up to approximately 52 weeks	TEAEs, defined as AEs that began or worsened in severity after the first dose of double-blind study drug and up to 30 days after receiving the last dose of double-blind study drug, were collected and reported. Cardiovascular events were considered as adverse events of special interest. Treatment-emergent = TE.
Percentage of Participants With the Indicated Event of Special Interest: Creatine Kinase Elevations	Up to approximately 52 weeks	TEAEs of special interest (AESIs) were predefined and monitored throughout the study. Creatine kinase elevations were assessed using the following preferred term: Blood creatine phosphokinase increased (system organ class: investigations).
Percentage of Participants With the Indicated Event of Special Interest: Hepatic Disorders	Up to approximately 52 weeks	Treatment-emergent AESIs were predefined and monitored throughout the study. TEAEs potentially related to hepatic events were assessed using the following preferred terms and laboratory abnormalities: aspartate aminotransferase (AST) increased, Alanine aminotransferase (ALT) increased, Hepatic enzyme increased, Blood bilirubin increased, liver function test (LFT) abnormal, LFT increased, hepatic enzyme abnormal, transaminases increased, potential Hy's Law cases (PHLC) \[AST and (\&)/or ALT \>3 x upper limit of normal (ULN) with concurrent total bilirubin \>2 x ULN\], AST and/or ALT \>3 x ULN, and total bilirubin \>2 x ULN (system organ class: investigations). AST and ALT values were repeated and confirmed. "Repeated and confirmed" was defined as a participant having the last on-study LFT \> x ULN, the last on-treatment LFT \> x ULN, or LFT \> x ULN followed by another LFT \> x ULN.
Percentage of Participants With the Indicated Event of Special Interest: Hypoglycemia	Up to approximately 52 weeks	Treatment-emergent AESIs were predefined and monitored throughout the study. Hypoglycemia was assessed using the following preferred terms: hypoglycaemia (system organ class: metabolism and nutrition disorders); blood glucose abnormal and blood glucose decreased (system organ class: investigations). The percentage of unique participants is reported in the "Overall hypoglycemia AESIs" category; a participant could have been represented in more than one of the individual hypoglycemia AESIs.
Percentage of Participants With the Indicated Event of Special Interest: Metabolic Acidosis	Up to approximately 52 weeks	Treatment-emergent AESIs were predefined and monitored throughout the study. Metabolic acidosis was assessed using the preferred term metabolic acidosis (system organ class: metabolism and nutrition disorders).
Percentage of Participants With the Indicated Event of Special Interest: Muscular Disorder	Up to approximately 52 weeks	Treatment-emergent AESIs were predefined and monitored throughout the study. Muscular safety was assessed using the following preferred terms and laboratory abnormalities: myalgia, muscle spasms, pain in extremity, muscular weakness (system organ class: musculoskeletal and connective tissue disorders), and creatine kinase \>5 ULN (repeated and confirmed). The percentage of unique participants is reported in the "Overall muscular disorder AESIs" category; a participant could have been represented in more than one of the individual muscular disorder AESIs.
Percentage of Participants With the Indicated Event of Special Interest: Neurocognitive Disorder	Up to approximately 52 weeks	Treatment-emergent AESIs were predefined and monitored throughout the study. Neurocognitive disorder was assessed using the following preferred terms: memory impairment, amnesia, and cognitive disorder (system organ class: nervous system disorders); confusional state and disorientation (system organ class: psychiatric disorders). The percentage of unique participants is reported in the "Overall neurocognitive disorder AESIs" category; a participant could have been represented in more than one of the individual neurocognitive disorder AESIs.
Percentage of Participants With Treatment-emergent Adverse Events (TEAEs)	Up to approximately 52 weeks	TEAEs, defined as adverse events (AEs) that began or worsened in severity after the first dose of double-blind study drug and up to 30 days after receiving the last dose of double-blind study drug, were collected and reported.
Percentage of Participants With the Indicated Event of Special Interest: New Onset or Worsening Diabetes Mellitus	Up to approximately 52 weeks	Treatment-emergent AESIs were predefined and monitored throughout the study. New onset or worsening diabetes was assessed using the following preferred terms: type 2 diabetes mellitus, diabetes mellitus, hyperglycaemia, glucose tolerance impaired, diabetes mellitus inadequate control, and impaired fasting glucose (system organ class: metabolism and nutrition disorders); blood glucose increased, glycosylated haemoglobin increased, blood glucose abnormal, and glucose urine present (system organ class: investigations); and glycosuria (system organ class: renal and urinary disorders). The percentage of unique participants is reported in the "Overall new onset/worsening diabetes mellitus AESIs" category; a participant could have been represented in more than one of the individual new onset/worsening diabetes mellitus AESIs.
Percentage of Participants With the Indicated Event of Special Interest: Renal Disorder	Up to approximately 52 weeks	Treatment-emergent AESIs were predefined and monitored throughout the study. TEAEs potentially related to renal events were assessed using the following preferred terms: renal failure, renal impairment, acute kidney injury (system organ class: renal and urinary disorders); blood creatinine increased, glomerular filtration rate decreased, blood urea increased, estimated glomerular filtration rate (eGFR) \<30 milliliter per minute per 1.73 square meter (ml/min/1.73m\^2), and change from baseline in creatinine \>1 mg/dL (system organ class: investigations); and gout (system organ class: metabolism and nutrition disorders). The percentage of unique participants is reported in the "Overall renal disorder AESIs" category; a participant could have been represented in more than one of the individual renal disorder AESIs.
Change From Baseline to Week 52 in Uric Acid (Urate) Level	Baseline and Week 52	Blood samples were drawn at defined time points during the course of the study to monitor uric acid (urate) levels.
Change From Baseline to Week 52 in Creatinine Level	Baseline and Week 52	Blood samples were drawn at defined time points during the course of the study to monitor creatinine levels.
Change From Baseline to Week 52 in Hemoglobin Level	Baseline and Week 52	Blood samples were drawn at defined time points during the course of the study to monitor hemoglobin levels.

Secondary Outcome Measures

Name	Time	Method
Percent Change From Baseline to Week 12 in Low-density Lipoprotein Cholesterol (LDL-C)	Baseline; Week 12	Blood samples were drawn after a minimum 10-hour fast (water was allowed) at pre-specified intervals. Samples were collected and analyzed for LDL-C. Baseline was defined as the mean of the values at screening (Week -2) and predose Day 1/Week 0. Percent change from baseline was calculated as: \[(LDL-C value at Week 12 minus Baseline value) divided by (Baseline Value)\] multiplied by 100. Missing data were imputed with the use of a pattern-mixture model to account for adherence to the trial regimen. Least Square mean= LS mean. Percent change was analyzed using the analysis of covariance (ANCOVA) method, which included treatment, randomization stratum as factors, and baseline value as covariate.
Absolute Change From Baseline to Week 12 in LDL-C	Baseline; Week 12	Blood samples were drawn after a minimum 10-hour fast (water was allowed) at pre-specified intervals. Samples were collected and analyzed for LDL-C. Baseline was defined as the mean of the values at screening (Week -2) and predose Day 1/Week 0. Absolute change from baseline was calculated as: LDL-C value at Week 12 minus Baseline value. Missing data were imputed with the use of a pattern-mixture model to account for adherence to the trial regimen.